Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.39 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.39 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.39 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | BRS3 | P32247 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 3/20 | 0.36 |
| ▸ | ATP4B | P51164 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497852 | 1.00 | DDAH1 (0.39) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL7563072 | 0.99 | DDAH1 (0.39) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL6545460 | 0.91 | DDAH1 (0.41) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL3850802 | 0.88 | AGXT (0.39) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL5935831 | 0.87 | DDAH1 (0.39) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL2943585 | 0.86 | DDAH1 (0.40) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL12438867 | 0.82 | DDAH1 (0.39) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL15762342 | 0.82 | DDAH1 (0.47) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL9793480 | 0.81 | AGXT (0.41) | DDAH1ENGASESARM1IDO2WDR5 | |
| SCHEMBL7852684 | 0.81 | KMT2A (0.42) | DDAH1ENGASESARM1IDO2WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | claimed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | claimed |
| EP-3512519-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2019-07-24 | — | — | EP | claimed |
| US-20180325921-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | MERITAGE PHARMA, INC. (US) | 2018-11-15 | — | — | US | claimed |
| WO-2018053190-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-22 | — | — | WO | claimed |
| US-20180071302-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-15 | — | — | US | claimed |
| EP-2214677-B1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | MERITAGE PHARMA INC (US) | 2017-08-30 | — | — | EP | claimed |
| US-20160235769-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | MERITAGE PHARMA, INC. (US) | 2016-08-18 | — | — | US | claimed |
| EP-1906939-B1 | USE OF A PARTIALLY NEUTRALIZED, ANIONIC (METH)ACRYLATE COPOLYMER AS A COATING FOR THE PRODUCTION OF A MEDICAMENT RELEASING ACTIVE SUBSTANCE AT REDUCED PH VALUES | EVONIK ROEHM GMBH (DE) | 2016-06-01 | — | — | EP | claimed |
| EP-2604256-B1 | Multi layer coatings | HEXAL AG (DE) | 2016-04-13 | — | — | EP | claimed |
| US-6362202-B1 | GASTROINTESTINAL DISORDERS | SEPRACOR INC. | 2002-03-26 | — | — | US | claimed |
| US-6353005-B1 | TREATMENT OF GASTROINTESTINAL DISORDERS | SEPRACOR, INC. | 2002-03-05 | — | — | US | claimed |
| US-20020010196-A1 | Hydroxyomeprazole compositions | YELLE WILLIAM E (US) | 2002-01-24 | — | — | US | claimed |
| EP-1156853-A2 | METHODS AND COMPOSITIONS USING (-) NORCISAPRIDE IN COMBINATION WITH PROTON PUMP INHIBITORS OR H 2? RECEPTOR ANTAGONISTS | Sepracor Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1156852-A2 | METHODS AND COMPOSITIONS USING (+) NORCISAPRIDE IN COMBINATION WITH PROTON PUMP INHIBITORS OR H 2? RECEPTOR ANTAGONISTS | Sepracor Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| US-6294586-B1 | ADMINISTERING HYDROXYOMEPRAZOLE OR ITS SALT TO HUMAN FOR THERAPY OF ULCERS | SEPRACOR INC. | 2001-09-25 | — | — | US | claimed |
| EP-1082114-A1 | HYDROXYOMEPRAZOLE COMPOSITIONS AND USES | SEPRACOR, INC. (US) | 2001-03-14 | — | — | EP | claimed |
| WO-2000051584-A2 | METHODS AND COMPOSITIONS USING (-) NORCISAPRIDE IN COMBINATION WITH PROTON PUMP INHIBITORS OR H2 RECEPTOR ANTAGONISTS | SEPRACOR INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000051583-A2 | METHODS AND COMPOSITIONS USING (+) NORCISAPRIDE IN COMBINATION WITH PROTON PUMP INHIBITORS OR H2 RECEPTOR ANTAGONISTS | SEPRACOR INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999056746-A1 | HYDROXYOMEPRAZOLE COMPOSITIONS AND USES | SEPRACOR INC. (US) | 1999-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | DDAH1 684/4885ENGASE 1474/4885SARM1 3323/4885 |
| US-20180325921-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | FABP2, FABP6, PTGES2 | DDAH1 4230/4885ENGASE 317/4885SARM1 4440/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | DDAH1 684/4885ENGASE 1474/4885SARM1 3323/4885 |
| US-20160235769-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT | FABP2, FABP6, PTGES2 | DDAH1 4230/4885ENGASE 317/4885SARM1 4440/4885 |
| US-20180071302-A1 | SYK INHIBITORS | SYK, BTK, LYN | DDAH1 3425/4885ENGASE 2199/4885SARM1 2725/4885 |
| US-20020010196-A1 | Hydroxyomeprazole compositions | HRH2, PGA5, ATP6AP1 | DDAH1 3065/4885ENGASE 2878/4885SARM1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.